Karen F. Neumann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Karen F. Neumann has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Slachevsky
Universidad de Chile
1 shared publication Gonzalo Farías
Laboratory of Cellular & Molecular Neurosciences, Faculty of Sciences, University of Chile, Santiago, Chile
1 shared publication- Gonzalo Farías
Pontificia Universidad Católica de Chile, Chile
1 shared publication Leonardo P. Navarrete
1 shared publication- Leonel E. Rojo
Departamento de Biología, Facultad de Química y Biología, Universidad de Santiago de Chile, Santiago, Chile
1 shared publication Patricio Perez
Laboratory of Cellular & Molecular Neurosciences, Faculty of Sciences, University of Chile, Santiago, Chile
1 shared publication
Latest Publications
- 14 June 2011
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 25 (1) , 103-109
Human Platelets Tau: A Potential Peripheral Marker for Alzheimer's Disease
Platelets are a major peripheral reservoir of the amyloid-β protein precursor, so they have been considered as a potential biological marker of Alzheimer's disease (AD). Here, it is demonstrated that tau protein is also present in platelets and that
- 14 June 2011
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 25 (1) , 103-109
Human Platelets Tau: A Potential Peripheral Marker for Alzheimer's Disease
Platelets are a major peripheral reservoir of the amyloid-β protein precursor, so they have been considered as a potential biological marker of Alzheimer's disease (AD). Here, it is demonstrated that tau protein is also present in platelets and that
- 1 October 2008
- Published by Bentham Science Publishers Ltd. in Current Alzheimer Research
- Vol. 5 (5) , 438-447
Insulin Resistance and Alzheimers Disease: Molecular Links & Clinical Implications
Hyperinsulinemia as well as type II diabetes mellitus are among the risk factors for Alzheimers disease (AD). However, the molecular and cellular basis that link insulin resistance disorders and diabetes with AD are far from clear. Here, we discuss the potential molecular mechanisms that may explain the participation of these metabolic disorders in the pathogenesis of AD. The human brain uses glucose as a primary fuel; insulin secreted by the pancreas cross the bloodbrain barrier (BBB), reaching neurons and glial cells, and exerts a region-specific effect on glucose metabolism. Glucose homeostasis is critical for energy generation, neuronal maintenance, neurogenesis, neurotransmitter regulation, cell survival and synaptic plasticity. It also plays a key role in cognitive function. In an insulin resistance condition, there is a reduced sensitivity to insulin resulting in hyperinsulinemia; this condition persists for several years before becoming fullblown diabetes. Toxic levels of insulin negatively influence neuronal function and survival, and elevation of peripheral insulin concentration acutely increases its cerebrospinal fluid (CSF) concentration. Peripheral hyperinsulinemia correlates with an abnormal removal of the amyloid beta peptide (Aβ) and an increase of tau hyperphosphorylation as a result of augmented cdk5 and GSK3β activities. This leads to cellular cascades that trigger a neurodegenerative phenotype and decline in cognitive function. Chronic peripheral hyperinsulinemia results in a reduction of insulin transport across the BBB and a reduced insulin signaling in brain, altering all of insulins actions, including its anti-apoptotic effect. However, the increase in brain insulin levels resulting from its peripheral administration at optimal doses has shown a cognitionenhancing effect in patient with AD. Some drugs utilized in type II diabetes mellitus reduce cognitive impairment associated with AD. The link between insulin resistance and neurodegeneration and AD, and the possible therapeutic targets in preventing the insulin-resistance disorders are analyzed.
- 1 October 2008
- Published by Bentham Science Publishers Ltd. in Current Alzheimer Research
- Vol. 5 (5) , 438-447
Insulin Resistance and Alzheimers Disease: Molecular Links & Clinical Implications
Hyperinsulinemia as well as type II diabetes mellitus are among the risk factors for Alzheimers disease (AD). However, the molecular and cellular basis that link insulin resistance disorders and diabetes with AD are far from clear. Here, we discuss the potential molecular mechanisms that may explain the participation of these metabolic disorders in the pathogenesis of AD. The human brain uses glucose as a primary fuel; insulin secreted by the pancreas cross the bloodbrain barrier (BBB), reaching neurons and glial cells, and exerts a region-specific effect on glucose metabolism. Glucose homeostasis is critical for energy generation, neuronal maintenance, neurogenesis, neurotransmitter regulation, cell survival and synaptic plasticity. It also plays a key role in cognitive function. In an insulin resistance condition, there is a reduced sensitivity to insulin resulting in hyperinsulinemia; this condition persists for several years before becoming fullblown diabetes. Toxic levels of insulin negatively influence neuronal function and survival, and elevation of peripheral insulin concentration acutely increases its cerebrospinal fluid (CSF) concentration. Peripheral hyperinsulinemia correlates with an abnormal removal of the amyloid beta peptide (Aβ) and an increase of tau hyperphosphorylation as a result of augmented cdk5 and GSK3β activities. This leads to cellular cascades that trigger a neurodegenerative phenotype and decline in cognitive function. Chronic peripheral hyperinsulinemia results in a reduction of insulin transport across the BBB and a reduced insulin signaling in brain, altering all of insulins actions, including its anti-apoptotic effect. However, the increase in brain insulin levels resulting from its peripheral administration at optimal doses has shown a cognitionenhancing effect in patient with AD. Some drugs utilized in type II diabetes mellitus reduce cognitive impairment associated with AD. The link between insulin resistance and neurodegeneration and AD, and the possible therapeutic targets in preventing the insulin-resistance disorders are analyzed.